Inventor · disambiguated record
Lori Kunkel
Also filed as: KUNKEL LORI · KUNKEL LORI A
8 granted patents·8 pending applications·179 citations·filing 2000–2022
87Inventor score
Top patents by PatentIndex Score
16 records- 0196US7820161B1Treatment of autoimmune diseasesBIOGEN IDEC INC·Filed 2000·Granted Oct 26, 2010·133 cites·12 claims
- 0292US9212225B1Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Dec 15, 2015·17 cites·14 claims
- 0390US9803029B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Oct 31, 2017·11 cites·18 claims
- 0488US10626190B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2017·Granted Apr 21, 2020·3 cites·12 claims
- 0585US7973136B2Optimized anti-CD30 antibodiesXENCOR INC·Filed 2006·Granted Jul 5, 2011·7 cites·8 claims
- 0684US10738118B2Methods of using bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2016·Granted Aug 11, 2020·3 cites·21 claims
- 0782US9574006B2Optimized anti-CD30 antibodiesLAZAR GREGORY ALAN·Filed 2011·Granted Feb 21, 2017·5 cites·9 claims
- 0866US2018264107A1Treatment of autoimmune diseasesGENENTECH INC·Filed 2018·Application pending·0 cites
- 0965US2021024654A1Bispecific CD33 and CD3 Binding ProteinsAMPHIVENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1064US2014134164A1Treatment of multiple sclerosisBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 1163US2013273042A1Treatment of multiple sclerosisBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 1262US2013084289A1Treatment of multiple sclerosisGENENTECH INC·Filed 2012·Application pending·0 cites
- 1360US11753469B2Methods of using bispecific CD33 and CD3 binding proteinsANJI BRUNO LLC·Filed 2020·Granted Sep 12, 2023·0 cites·22 claims
- 1459US2012201818A1Treatment of multiple sclerosisCURD JOHN G·Filed 2012·Application pending·0 cites
- 1553US2010003252A1Blocking immune response to a graftGENENTECH INC·Filed 2009·Application pending·0 cites
- 1652US2022288204A1Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusionsELEVATION ONCOLOGY INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lori Kunkel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →